Multidisciplinary Management of Indolent Systemic Mastocytosis
ISM Content Hub
Cem Akin, MD, PhD, University of Michigan, and Daniel J. DeAngelo, MD, PhD, Harvard Medical School, discuss treatment options for indolent systemic mastocytosis. Tyrosine kinase inhibitor therapies have been shown to reduce symptoms in patients with moderate-to-severe disease. Diagnosis and treatment can be improved by using expertise of a multidisciplinary team that includes allergists, hematologists, and gastroenterologists.
